menu
    • menu
    [{"orgOrder":0,"company":"Exothera","sponsor":"CyanVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"CVXGA1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exothera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Exothera \/ CyanVac","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/ CyanVac"},{"orgOrder":0,"company":"Exothera","sponsor":"Rokote Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"FINCoVac 2.0","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exothera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Exothera \/ Rokote Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/ Rokote Laboratories"},{"orgOrder":0,"company":"Exothera","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"VALO-D102","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Exothera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Exothera \/ Exothera","highestDevelopmentStatusID":"2","companyTruncated":"Exothera \/ Exothera"},{"orgOrder":0,"company":"Exothera","sponsor":"Remedium","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"RMD 1101","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Exothera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Exothera \/ Remedium","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/ Remedium"}]

    Find Clinical Drug Pipeline Developments & Deals by Exothera

    Menu

    Exothera

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Exothera

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Exothera

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMD 1101

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Remedium

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Remedium and Exothera Partner On Scale-up And Demonstration Runs For AAV2-FGF18

                            Details : Remedium and Exothera will demonstrate the industrialization potential of Remedium’s RMD 1101 (AAV2-FGF18). Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18 for the tr...

                            Brand Name : RMD 1101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 22, 2023

                            Lead Product(s) : RMD 1101

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Remedium

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Exothera

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Exothera

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VALO-D102

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Valo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Valo Therapeutics Selects Exothera to Develop Large-Scale Oncolytic Adenovirus Manufacturing

                            Details : VALO-D102 is a fundamental component of the company’s proprietary PeptiCRAd (peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform. PeptiCRAd combines two cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide va...

                            Brand Name : VALO-D102

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 11, 2023

                            Lead Product(s) : VALO-D102

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Valo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Exothera

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Exothera

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FINCoVac 2.0

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Rokote Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Rokote Laboratories Selects Exothera For GMP Manufacturing of Its Second-​generation Coronavirus Vaccine

                            Details : The FINCoVac vaccine is designed to program the nasopharyngeal cells to produce immune response-inducing modified SARS-CoV-2-viral spike protein. FINCoVac 2.0 represents an easy-to-administer booster for those who are already fully vaccinated with other ...

                            Brand Name : FINCoVac 2.0

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 01, 2022

                            Lead Product(s) : FINCoVac 2.0

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Rokote Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Exothera

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Exothera

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVXGA1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : CyanVac

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CyanVac Selects Exothera for the Development and GMP Manufacturing of Its Covid-19 Intranasal Vaccine Candidat...

                            Details : Exothera will be responsible for the fast-track development of a manufacturing process for CyanVac’s COVID-19 vaccine candidate, CVXGA1, using the unique scale-X™ platform.

                            Brand Name : CVXGA1

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 24, 2021

                            Lead Product(s) : CVXGA1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : CyanVac

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth